Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

“A dynamic in vitro model of Down Syndrome neurogenesis with Trisomy 21 gene dosage correction”

View ORCID ProfilePrakhar Bansal, Erin. C Banda, View ORCID ProfileHeather R. Glatt-Deeley, Christopher E. Stoddard, View ORCID ProfileDarcy T. Ahern, View ORCID ProfileYuvabharath Kondaveeti, View ORCID ProfileMichael Nicouleau, View ORCID ProfileStefan F. Pinter
doi: https://doi.org/10.1101/2022.05.11.491519
Prakhar Bansal
1Graduate Program in Genetics and Developmental Biology, UCONN Health, University of Connecticut, Farmington, CT, United States
2Department of Genetics and Genome Sciences, UCONN Health, University of Connecticut, Farmington, CT, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Prakhar Bansal
Erin. C Banda
2Department of Genetics and Genome Sciences, UCONN Health, University of Connecticut, Farmington, CT, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather R. Glatt-Deeley
2Department of Genetics and Genome Sciences, UCONN Health, University of Connecticut, Farmington, CT, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Heather R. Glatt-Deeley
Christopher E. Stoddard
3Cell and Genome Engineering Core, UCONN Health, University of Connecticut, Farmington, CT, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darcy T. Ahern
1Graduate Program in Genetics and Developmental Biology, UCONN Health, University of Connecticut, Farmington, CT, United States
2Department of Genetics and Genome Sciences, UCONN Health, University of Connecticut, Farmington, CT, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Darcy T. Ahern
Yuvabharath Kondaveeti
2Department of Genetics and Genome Sciences, UCONN Health, University of Connecticut, Farmington, CT, United States
4Enzerna Biosciences, Morrisville, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yuvabharath Kondaveeti
Michael Nicouleau
5Early Drug Discovery Unit, Montreal Neurology Institute, McGill University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael Nicouleau
Stefan F. Pinter
1Graduate Program in Genetics and Developmental Biology, UCONN Health, University of Connecticut, Farmington, CT, United States
2Department of Genetics and Genome Sciences, UCONN Health, University of Connecticut, Farmington, CT, United States
6Institute for Systems Genomics, University of Connecticut, Farmington, CT, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stefan F. Pinter
  • For correspondence: spinter@uchc.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

ABSTRACT/SUMMARY

Excess gene dosage from human chromosome 21 (HSA21), due to trisomy or translocation of HSA21 material, causes Down syndrome (DS). Trisomy 21 (T21) results in a large number of developmental and ongoing cellular phenotypes, raising the critical question of whether some of the latter may remain amenable to intervention after development. To generate an in vitro model of DS neurogenesis with dynamic T21 dosage, we derived T21 human induced pluripotent stem cells (hiPSCs) alongside otherwise isogenic euploid controls from mosaic DS fibroblasts, and equipped one distinct HSA21 copy with a new inducible XIST transgene. Phased genotyping enables us to apply this unique biological resource to allelic transcriptome analyses that demonstrate that T21 silencing by XIST is largely complete and irreversible in hiPSCs. Differential expression analysis reveals T21 neural lineages and hiPSCs share suppressed translation and mitochondrial pathways, and activate cellular stress responses. When XIST is induced prior to the neural progenitor stage, T21 dosage correction suppresses a pronounced skew towards excessive astrogenesis in T21 neural differentiation. Because our XIST transgene remains inducible in post-mitotic T21 neurons and astrocytes, this dynamic model of HSA21 gene dosage will empower systematic exploration of cellular and transcriptional T21 phenotypes that depend on acute T21 gene dosage in differentiated cell types.

Competing Interest Statement

The authors have declared no competing interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 11, 2022.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
“A dynamic in vitro model of Down Syndrome neurogenesis with Trisomy 21 gene dosage correction”
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
“A dynamic in vitro model of Down Syndrome neurogenesis with Trisomy 21 gene dosage correction”
Prakhar Bansal, Erin. C Banda, Heather R. Glatt-Deeley, Christopher E. Stoddard, Darcy T. Ahern, Yuvabharath Kondaveeti, Michael Nicouleau, Stefan F. Pinter
bioRxiv 2022.05.11.491519; doi: https://doi.org/10.1101/2022.05.11.491519
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
“A dynamic in vitro model of Down Syndrome neurogenesis with Trisomy 21 gene dosage correction”
Prakhar Bansal, Erin. C Banda, Heather R. Glatt-Deeley, Christopher E. Stoddard, Darcy T. Ahern, Yuvabharath Kondaveeti, Michael Nicouleau, Stefan F. Pinter
bioRxiv 2022.05.11.491519; doi: https://doi.org/10.1101/2022.05.11.491519

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Developmental Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (3514)
  • Biochemistry (7367)
  • Bioengineering (5347)
  • Bioinformatics (20326)
  • Biophysics (10046)
  • Cancer Biology (7777)
  • Cell Biology (11353)
  • Clinical Trials (138)
  • Developmental Biology (6453)
  • Ecology (9980)
  • Epidemiology (2065)
  • Evolutionary Biology (13357)
  • Genetics (9373)
  • Genomics (12614)
  • Immunology (7725)
  • Microbiology (19104)
  • Molecular Biology (7465)
  • Neuroscience (41153)
  • Paleontology (301)
  • Pathology (1235)
  • Pharmacology and Toxicology (2142)
  • Physiology (3180)
  • Plant Biology (6880)
  • Scientific Communication and Education (1276)
  • Synthetic Biology (1900)
  • Systems Biology (5328)
  • Zoology (1091)